KRAS and non-small cell lung carcinoma: However, the outcomes of contemplative research consisting of 530 formerly treated patients with NSCLC receiving nivolumab revealed that the KRAS status was not consistent evidence of immunotherapeutic efficiency in survival rates and response [139].